Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) was the recipient of a significant drop in short interest in October. As of October 31st, there was short interest totalling 13,435,509 shares, a drop of 13.8% from the October 13th total of 15,586,182 shares. Approximately 13.1% of the shares of the stock are sold short. Based on an average daily volume of 742,164 shares, the days-to-cover ratio is currently 18.1 days.

In other Lexicon Pharmaceuticals news, CEO Lonnel Coats bought 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 15th. The stock was purchased at an average price of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the transaction, the chief executive officer now owns 42,985 shares of the company’s stock, valued at approximately $425,981.35. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Public Equities L.P. Invus bought 145,680 shares of the business’s stock in a transaction that occurred on Friday, November 10th. The shares were acquired at an average price of $9.74 per share, with a total value of $1,418,923.20. The disclosure for this purchase can be found here. Insiders have purchased 764,626 shares of company stock valued at $7,477,803 in the last quarter. 5.77% of the stock is currently owned by company insiders.

Large investors have recently bought and sold shares of the company. State of Wisconsin Investment Board bought a new stake in shares of Lexicon Pharmaceuticals in the 2nd quarter valued at approximately $510,000. Goldman Sachs Group Inc. lifted its stake in shares of Lexicon Pharmaceuticals by 17.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 134,043 shares of the biopharmaceutical company’s stock valued at $2,205,000 after purchasing an additional 20,379 shares during the last quarter. Kornitzer Capital Management Inc. KS bought a new stake in shares of Lexicon Pharmaceuticals in the 3rd quarter valued at approximately $9,420,000. Pictet Asset Management Ltd. lifted its stake in shares of Lexicon Pharmaceuticals by 10.4% in the 2nd quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after purchasing an additional 6,400 shares during the last quarter. Finally, First Mercantile Trust Co. lifted its stake in shares of Lexicon Pharmaceuticals by 11.2% in the 2nd quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after purchasing an additional 1,227 shares during the last quarter.

Several analysts recently issued reports on LXRX shares. Wedbush reiterated an “ourperform” rating and set a $39.00 target price on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. Zacks Investment Research cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. BidaskClub cut Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, August 2nd. Cowen and Company restated a “hold” rating on shares of Lexicon Pharmaceuticals in a report on Tuesday, August 1st. Finally, Needham & Company LLC restated a “buy” rating and set a $21.00 price target on shares of Lexicon Pharmaceuticals in a report on Sunday, September 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Lexicon Pharmaceuticals has a consensus rating of “Hold” and an average price target of $28.75.

Lexicon Pharmaceuticals (NASDAQ LXRX) opened at $10.00 on Friday. The company has a debt-to-equity ratio of 1.09, a current ratio of 1.66 and a quick ratio of 1.65. Lexicon Pharmaceuticals has a 1-year low of $8.07 and a 1-year high of $18.00.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.07. The business had revenue of $26.94 million during the quarter, compared to analysts’ expectations of $27.97 million. Lexicon Pharmaceuticals had a negative return on equity of 111.68% and a negative net margin of 165.69%. The firm’s revenue for the quarter was down 2.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.35) EPS. analysts anticipate that Lexicon Pharmaceuticals will post -1.45 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Short Interest in Lexicon Pharmaceuticals, Inc. (LXRX) Declines By 13.8%” was originally published by Watch List News and is owned by of Watch List News. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.watchlistnews.com/short-interest-in-lexicon-pharmaceuticals-inc-lxrx-declines-by-13-8/1708415.html.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.